Kędzierska Magdalena, Bańkosz Magdalena
Department of Chemotherapy, Medical University of Lodz, Copernicus Memorial Hospital of Lodz, 90-549 Lodz, Poland.
CUT Doctoral School, Faculty of Materials Engineering and Physics, Department of Material Engineering, Cracow University of Technology, 37 Jana Pawla II Av., 31-864 Krakow, Poland.
J Clin Med. 2024 Nov 25;13(23):7131. doi: 10.3390/jcm13237131.
Modern oncology increasingly relies on the role of proteins as key components in cancer diagnosis, prognosis, and targeted therapy. This review examines advancements in protein biomarkers across several cancer types, including breast cancer, lung cancer, ovarian cancer, and hepatocellular carcinoma. These biomarkers have proven critical for early detection, treatment response monitoring, and tailoring personalized therapeutic strategies. The article highlights the utility of targeted therapies, such as tyrosine kinase inhibitors and monoclonal antibodies, in improving treatment efficacy while minimizing systemic toxicity. Despite these advancements, challenges like tumor resistance, variability in protein expression, and diagnostic heterogeneity persist, complicating universal application. The review underscores future directions, including the integration of artificial intelligence, advanced protein analysis technologies, and the development of combination therapies to overcome these barriers and refine personalized cancer treatment.
现代肿瘤学越来越依赖蛋白质作为癌症诊断、预后和靶向治疗的关键组成部分。本综述探讨了多种癌症类型(包括乳腺癌、肺癌、卵巢癌和肝细胞癌)中蛋白质生物标志物的进展。这些生物标志物已被证明对早期检测、治疗反应监测以及制定个性化治疗策略至关重要。文章强调了酪氨酸激酶抑制剂和单克隆抗体等靶向治疗在提高治疗效果同时将全身毒性降至最低方面的效用。尽管取得了这些进展,但肿瘤耐药性、蛋白质表达变异性和诊断异质性等挑战依然存在,使普遍应用变得复杂。该综述强调了未来的方向,包括人工智能的整合、先进的蛋白质分析技术以及联合疗法的开发,以克服这些障碍并完善个性化癌症治疗。